Cargando…

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Hilst, Jeroen CH, Moutschen, Michel, Messiaen, Peter E, Lauwerys, Bernard R, Vanderschueren, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831592/
https://www.ncbi.nlm.nih.gov/pubmed/27110096
http://dx.doi.org/10.2147/BTT.S102954
_version_ 1782427103861407744
author van der Hilst, Jeroen CH
Moutschen, Michel
Messiaen, Peter E
Lauwerys, Bernard R
Vanderschueren, Steven
author_facet van der Hilst, Jeroen CH
Moutschen, Michel
Messiaen, Peter E
Lauwerys, Bernard R
Vanderschueren, Steven
author_sort van der Hilst, Jeroen CH
collection PubMed
description INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. RESULTS: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. CONCLUSION: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine.
format Online
Article
Text
id pubmed-4831592
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48315922016-04-22 Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature van der Hilst, Jeroen CH Moutschen, Michel Messiaen, Peter E Lauwerys, Bernard R Vanderschueren, Steven Biologics Original Research INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. RESULTS: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. CONCLUSION: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Dove Medical Press 2016-04-04 /pmc/articles/PMC4831592/ /pubmed/27110096 http://dx.doi.org/10.2147/BTT.S102954 Text en © 2016 van der Hilst et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
van der Hilst, Jeroen CH
Moutschen, Michel
Messiaen, Peter E
Lauwerys, Bernard R
Vanderschueren, Steven
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_full Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_fullStr Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_full_unstemmed Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_short Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
title_sort efficacy of anti-il-1 treatment in familial mediterranean fever: a systematic review of the literature
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831592/
https://www.ncbi.nlm.nih.gov/pubmed/27110096
http://dx.doi.org/10.2147/BTT.S102954
work_keys_str_mv AT vanderhilstjeroench efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature
AT moutschenmichel efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature
AT messiaenpetere efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature
AT lauwerysbernardr efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature
AT vanderschuerensteven efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature